Validation of 3‐ and 5‐point severity scales to assess ARIA‐E

Validation of 3‐ and 5‐point severity scales to assess ARIA‐E

Abstract INTRODUCTION Anti‐amyloid‐β (Aβ) monoclonal antibodies (mAbs) offer the promise of disease modification and are emerging treatment options in Alzheimer's disease. Anti‐Aβ mAbs require brain magnetic resonance imaging (MRI) examinations to detect anti‐amyloid‐induced amyloid‐related ima...

Full description

Bibliographic Details
Main Authors: Luc Bracoud, Gregory Klein, Marco Lyons, Marzia A. Scelsi, Jakub Wojtowicz, Szofia Bullain, Derk Purcell, Jochen B. Fiebach, Jerome Barakos, Joyce Suhy
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
Alzheimer's disease
amyloid
amyloid plaques
amyloid beta
diagnostic imaging
Online Access:https://doi.org/10.1002/dad2.12503

Internet

https://doi.org/10.1002/dad2.12503

Similar Items